Abstract
Activation of the prostaglandin D2 receptor (PTGDR) may contribute to pulmonary vasodilation, bronchoconstriction, recruitment of eosinophils, basophils and T-lymphocytes, and enhanced synthesis of leukotriene C4. We investigated whether polymorphisms of the leukotriene C4 synthase (LTC4S) −444A/C and PTGDR −441T/C were associated with clinical phenotypes and responsiveness to leukotriene receptor antagonist (LTRA) in Korean asthmatic children. We enrolled 270 normal and 870 asthmatic children. We prescribed montelukast (5 mg per day) to 100 of asthmatic children, and analyzed the responsiveness to LTRA by exercise challenge tests. Polymorphisms were genotyped by PCR–restriction fragment length polymorphism. As the number of minor alleles of the PTGDR −441T/C and LTC4S −444A/C polymorphisms increased, the log total eosinophil counts increased in atopic asthmatic children (P-value=0.03). We found a significant association between responsiveness to montelukast and the PTGDR polymorphism (P-value=0.038). However, the LTC4S −444A/C and PTGDR −441T/C were not associated with the susceptibility for asthma (LTC4S, AA versus AC+CC, adjusted odds ratio of 0.98 (95% confidence interval, 0.73–1.31); PTGDR, TT versus TC+CC, adjusted odds ratio of 0.90 (95% confidence interval, 0.68–1.19)) or clinical phenotypes (P-value>0.05). The effects of the PTGDR and LTC4S polymorphisms on the enhancement of eosinophil counts were additive in the Korean children with asthma. In addition, the PTGDR polymorphism seems to be associated with the responsiveness to LTRA. Therefore, therapies that target the PTGDR may be useful for modulating the responsiveness to LTRA.
Similar content being viewed by others
Introduction
Asthma is a complex disease that results from interactions among multiple genes and environmental factors.1 The Th2 cytokine-driven inflammatory mechanisms have an important role in the pathophysiology of asthma.2 Th2 cytokines, such as interleukin-4, interleukin-13 and interleukin-5, participate in the synthesis of immunoglobulin E (IgE),3 and promote allergic eosinophilic inflammation and airway remodeling.4
Asthma is often triggered by mast cells that are activated by an IgE-mediated allergic challenge.5 Activated mast cells produce a variety of chemical mediators including prostaglandin D2 (PGD2), which is the major cyclooxygenase metabolite of arachidonic acid, in response to allergen exposure.6 PGD2 may contribute to pulmonary vasodilation, bronchoconstriction, and the recruitment of eosinophils, basophils and T-lymphocytes.7, 8, 9 PGD2 exerts its biological actions through the PGD2 receptor (PTGDR), which is localized to chromosome 14q22.1 and has been associated with asthma.10 The association between asthma and PTGDR function has been recently studied with a mouse model. PTGDR-knockout mice (PTGDR−/−) show only marginal infiltration of eosinophils, reduced levels of Th2 cytokines and accumulation of lymphocytes in the lungs, and no development of bronchial hyperresponsiveness on ovalbumin challenge compared with wild-type controls.8 These findings suggest that asthma could be inhibited when the PTGDR is absent. The existence of genetic variants in the promoter region of the PTGDR (−549, −441 and −197) have been reported for several ethnic groups.11, 12, 13, 14 These three polymorphisms were not always related to asthma, but they may have a role in controlling PTGDR expression. Therefore, the PTGDR may serve as a therapeutic target for asthma.
Leukotriene C4 (LTC4) and PGD2 are converted from arachidonic acid by 5-lipoxygenase and cyclooxygenase, respectively.15, 16, 17 However, the results of a recent study showed that PGD2 activated eosinophils and enhanced LTC4 synthesis in vivo.18 Accumulating evidence suggests that the cysteinyl leukotrienes (cysLTs) are the primary mediators of exercise-induced bronchoconstriction (EIB), as demonstrated by the detection of cysLTs in the airways,19 increased levels of urinary leukotriene E420 and increased levels of cysLTs in exhaled breath condensates,21 and in induced sputum22 from children with EIB. Therefore, we presume that the function of PGD2 may affect the response of the leukotriene receptor antagonist (LTRA), which inhibits the effect of leukotriene, although the PTGDR is not directly included in the LTRA pathway. The purpose of this study was to understand the relationship between the presence of polymorphisms in the promoter region of the genes for leukotriene C4 synthase (LTC4S) and PTGDR and the responsiveness to a LTRA.
Materials and methods
Subjects
We collected DNA samples from subjects who came to asthma and allergy clinics and general pediatric clinics at the Asan Medical Center (270 normal children and 870 children with asthma). The normal controls had no history of asthma, other allergic diseases or airway hyperresponsiveness (PC20 (concentration of methacholine that provoked a 20% fall in FEV1) >16 mg ml−1). They had negative result of skin prick tests, normal total IgE values (⩽100 IU ml−1) and normal lung function tests. We enrolled all children with asthma who were diagnosed (i) by their physician and met the criteria set forth in the American Thoracic Society guidelines; (ii) on the basis of a history of dyspnea and wheezing during the previous 12 months; or (iii) as having a >12% FEV1 after β2-agonist inhalation, a methacholine provocation test indicating airway hyperresponsiveness (PC20 <16 mg ml−1) or both. The subjects who satisfied the American Thoracic Society guidelines and had negative result of skin prick tests and normal total IgE levels (⩽100 IU ml−1) defined non-atopic asthmatics.
The subjects with asthma who were included in the drug responsiveness analysis performed an exercise provocation test, from the middle of July to the beginning of November, with all measurements conducted between 1500 and 17 hours. The FEV1 of this subjects decreased by at least 15% following the standardized exercise challenge. Subjects were excluded from the study if they had been treated in the previous 3 months with orally administered or inhaled corticosteroids, long-acting β2-agonists or a LTRA other than a short-acting β2-agonist, or if they had experienced an exacerbation in their asthma or a respiratory tract infection within the 4 weeks before entering the study.
This study was approved by the ethics committee of the Asan Medical Center Institutional Review Board, and written informed consent was obtained from the parents of all study participants.
Serum IgE and skin prick tests
Total serum IgE concentrations were measured by fluorescent enzyme immunoassay using the AutoCAP System (Phadia AB, Uppsala, Sweden). Skin prick tests were performed using a panel of 27 common Korean aeroallergens (Allergopharma, Reinbek, Germany). A test was considered ‘positive’ if the maximum wheal diameter was 3 mm.
LTRA drug responsiveness study design
In all, 100 subjects with asthma performed an exercise challenge test twice both before and after receiving their daily dose of montelukast (5 mg per day) for 8 weeks. The standardized exercise challenge consisted of 8 min of free running outdoors, as previously described.23, 24 Subjects showing a ⩾10% post-treatment improvement in the maximum percentage fall in FEV1 were defined as ‘responders’, and those subjects exhibiting <0% improvement (worsened values) in the maximum percentage fall in FEV1 were defined as ‘non-responders’. Improvement (%) was calculated with the following formula: 100 × [(maximum percentage fall in FEV1 before treatment−maximum percentage fall in FEV1 after treatment)/maximum percentage fall in FEV1 before treatment].
Genotyping
DNA was isolated from blood samples from each subject using a G-DEX II kit (Intron, Seoul, Korea). PCR–restriction fragment length polymorphism was used to determine the polymorphisms. The primer pairs and annealing temperatures were as follows: 5′-cgagttcttggccaccccagttcaaacaccagcacaa-3′ and 5′-ggagcaggccagtgaaga-3′ and 57 °C for the PTGDR −441T/C (rs803010); 5′-CCTCAGTTTCCTCGCCTATG-3′ and 5′-GGCCAAGAACTCGAAAGATG-3′ and 56 °C for the PTGDR −549T/C (rs8004654); and 5′-tacaacgactaaggctggca-3′ and 5′-gctgtgtgtgaaggcgagc-3′ and 58°C for the LTC4S −444A/C (rs730012). The restriction enzymes were as follows: Mfe I (New England BioLabs, Beverly, MA, USA) digested the PTGDR−441T allele into 195 and 35 bp fragments, HpyAV (New England BioLabs) digested the PTGDR −549C allele into 125 and 74 bp fragment and Msp I (New England BioLabs) digested the LTC4S −444C allele into 388, 169 and 32 bp fragments. To confirm the accuracy of restriction fragment length polymorphism analysis, we randomly selected 20% of the subjects for DNA sequencing of each polymorphism. The observed genotype distributions of the PTGDR −441T/C, −549T/C and LTC4S −444A/C did not deviate significantly from the Hardy–Weinberg equilibrium (P=0.377, P=0.372 and P=0.346, respectively).
Statistical analyses
The clinical parameters (for example, total IgE, PC20, total eosinophil count (TEC)) were converted into log10-based values in order to produce a normal distribution for the statistical analyses, and then the data were analyzed with Mann–Whitney U-tests. Subject demographic variables (for example, sex and age) were analyzed by multiple logistic regressions in order to determine whether or not the presence of particular alleles was disproportionate among the subjects. To analyze associations between the genotypes and asthma, we adopted a dominant model for the minor allele, assuming it was the risk allele and because relatively few individuals were homozygous for the risk alleles. An unconditional logistic regression analysis, adjusted for age and sex, was used to calculate the odds ratios, 95% confidence intervals and P-values. The relationship between clinical phenotype and genotype was tested using linear regression. The χ2-tests were used to examine the relationship between responder or non-responder status and the LTC4S and PTGDR polymorphisms. All statistical analyses were performed using SPSS 18.0 for Windows (SPSS, Chicago, IL, USA), and P-values of ⩽0.05 were considered statistically significant. And bootstrapping (1000 times) was carried out for significant association and combination between two polymorphisms.
Results
Clinical characteristics
We administered montelukast daily to 100 of the subjects with asthma, for 8 weeks, and subsequently divided the subjects into two groups: responders and non-responders. There were 92 subjects included in this analysis and, of these, 69 subjects (75%) were responders (⩾10% improvement) and 23 subjects (25%) were non-responders (<0% improvement). The improvement of the 92 subjects was calculated by a numerical formula, and the percentages ranged from −113.1% to 95.0%. We compared the responders and non-responders in terms of their eosinophil fraction, log IgE levels, log PC20 levels, baseline maximum percentage fall in FEV1 after exercise and pulmonary function, and there were no differences between the two groups. Sex ratio seems that there might be a difference, however, it is not different statistically (P=0.075 by χ2-test). The responders and non-responders were randomly selected among 278, exercise-induced asthmatics who performed the exercise challenge test and who showed positive, EIB. However, as usually the severe EIB (+) subjects suggested severe asthmatic patients, LTRA treatment only may be used in mild asthmatics if their parents prefer it. Therefore, the maximum % fall in FEV1 (%) differed in the subjects included in the LTRA study and in those who were excluded (Table 1).
Relationship between LTRA responsiveness and frequency of LTC4S and PTGDR polymorphisms
The PTGDR −549T/C and −441T/C polymorphisms were in almost complete linkage disequilibrium (D′=0.978), so we analyzed one among two polymorphisms. We chose a dominant model for the minor allele and analyzed the distributions of the LTC4S −444A/C and PTGDR −441T/C polymorphisms because the percentage of homozygous for the minor allele of the two polymorphisms was not >7.69%. The prevalence of the LTC4S −444A/C polymorphism did not differ between the responders and non-responders (P=0.702), but there was a higher number of non-responders that were heterozygous or homozygous for the C allele of the PTGDR −441T/C polymorphism (P=0.038, Table 2).
We investigated how combinations of the LTC4S −444A/C and PTGDR −441T/C polymorphisms influenced the responsiveness of the subjects to a LTRA. The possible polymorphism combinations were determined according to the dominant model, as listed in Table 3, afterward group II, III and IV compared with group I. A significant difference in combination was not observed among each group (Table 3).
Frequency of LTC4S and PTGDR polymorphisms in children with asthma
We analyzed the frequency of the LTC4S −444A/C and PTGDR −441T/C polymorphisms among the normal children and the children with asthma, atopic asthma or non-atopic asthma. The frequency of the minor allele of the LTC4S −444A/C polymorphism was 0.18 for the normal children and 0.17 for the children with asthma. The frequency of the minor allele of the PTGDR −441T/C polymorphism was 0.26 for the normal children and 0.25 for the children with asthma. The frequency of the minor allele for the children with asthma was identical to the frequency for the children with atopic asthma. The LTC4S −444A/C and PTGDR −441T/C polymorphisms were not significantly associated with children with asthma, atopic asthma or non-atopic asthma compared with normal children in an additive, recessive and dominant model (Table 4).
Relationship of eosinophils to the LTC4S −444A/C and the PTGDR −441T/C polymorphisms
Because leukotriene is secreted from eosinophils, a high TEC is one of the distinguishing features of asthma, and because PGD2 may contribute to the recruitment of eosinophils, we investigated the relationship between the number of eosinophils and the LTC4S −444A/C and PTGDR −441T/C polymorphisms in children with asthma or atopic asthma. Interestingly, as the number of minor alleles of these two polymorphisms increased, the log TEC increased in the children with atopic asthma (P=0.03). There was a tendency for the log TEC to increase in the children with asthma, but the effect was not statistically significant (Figure 1). We compared the difference in eosinophil counts in non-atopic asthmatics and atopic asthmatics in each combination group. According to the comparative results, log TEC was higher in atopic asthmatics than in non-atopic asthmatics (Supplementary Table 1).
Discussion
In this study, we have shown a significant effect of the presence of the PTGDR −441T/C polymorphism on responsiveness to a LTRA during an exercise challenge model of bronchial responsiveness in children with asthma. In addition, we have found a correlation between TEC increment and the combined presence of the PTGDR −441T/C and LTC4S −444A/C polymorphisms in children with atopic asthma. However, the presence of these two polymorphisms was not associated with asthma susceptibility in Korean children with asthma.
The PTGDR is located at chromosome 14q22.1 and is the receptor for PGD2 that may contribute to the asthma phenotype, which is characterized by pulmonary vasodilation, bronchoconstriction and recruitment of eosinophils.7, 8, 9 The effects of the PTGDR on asthma were shown with a mouse study; the asthmatic symptoms of PTGDR−/− mice were improved compare with wild-type mice.8 In addition, PGD215 and LTC416, 17 are both derived from arachidonic acid. However, the relationship between the PTGDR and responsiveness to a LTRA has not been investigated. We considered three single-nucleotide polymorphisms (SNPs; −197T/C, −441T/C and −549T/C) in the PTGDR gene. These three SNPs have been investigated in many previous studies. The −441T/C polymorphism was associated with asthma development in the white population11 but not in the Mexican population.12 The −549T/C and −197T/C polymorphisms are associated with asthma development in the black11 and Caucasian populations13, respectively. However, three SNPs were not significant in the Chinese population, as noted in our results.14 These findings may be caused by the difference in allele frequency in a particular ethnic group. In fact, we confirmed the difference of 0.2 to 0.4 in Asians and CEPH (Utah residents with ancestry from northern and western Europe) according to the HapMap data. Although it is not a data from Asian, a minor allele frequency of −197T/C polymorphism is very low (about 10%) in European. And two SNPs (−441T/C and −549T/C) were in strong linkage disequilibrium. Therefore, we examined the relationship between the PTGDR −441T/C polymorphism and responsiveness to LTRA, and found that subjects with heterozygous or homozygous C alleles were more likely to be non-responders. In addition, we analyzed the effect of the combined presence of the PTGDR −441T/C and LTC4S −444A/C polymorphisms because LTRA improves the asthmatic symptoms of subjects by impeding the function of leukotriene. The PGD2 recruits eosinophils8 and induces the synthesis of LTC4 by stimulating the eosinophils.18 Also the LTC4S −444A/C polymorphism was associated with leukotriene production and asthma in several independent studies.25, 26 Although the LTC4S −444A/C polymorphism was always not associated with asthma susceptibility or severity,26, 27 this polymorphism is universally most common SNP. Therefore, we investigated a combined effect of the PTGDR (−441T/C) and LTC4S (−444A/C) polymorphisms in EIB model after treatment with LTRA. However, there were no significant differences between the responders and non-responders of this study when we analyzed the combined frequencies of the PTGDR and LTC4S polymorphisms.
PGD2 may contribute to the recruitment of eosinophils,8 and LTC4, a potent biomarker produced by eosinophils,28 has been shown to be a strong mediator of bronchoconstriction in EIB.29 We previously reported that children with asthma who also experienced EIB had significantly higher TEC.30 In addition, the results of several studies suggest that the presence and severity of EIB is significantly associated with the number of eosinophils measured from the blood and sputum of subjects with asthma.31, 32, 33, 34 Therefore, we hypothesized that eosinophils contribute to the mechanisms underlying EIB and the therapeutic effects of LTRA therapy, and then we investigated the effects of polymorphism combinations on LTRA drug responsiveness and on TEC in children with asthma. Interestingly, we found that the presence of the PTGDR −441C and LTC4S −444C alleles appeared to be associated with increased TEC in children with asthma, especially children with atopic asthma. In Supplementary Table 1, the reason for the higher TEC in atopic asthmatics than in non-atopic asthmatics, may be atopy and is not a combination of two polymorphisms. In fact, we confirmed that log TEC increases if log IgE increased in our asthmatics (Supplementary Figure 1). We additionally analyzed a change of eosinophil count according to combination of the two SNPs in responder (69 subjects), non-responder (23 subjects) and total 100 subjects of LTRA, respectively. However, there were not increasing trend of eosinophil counts (data not shown). Therefore, the association between responsiveness to LTRA in 100 subjects and increased number of eosinophils in atopic asthmatics may be not direct because of two different groups of subjects. However, individuals with C allele of the PTGDR have high eosinophil counts, the PTGDR was expressed on eosinophil and leukotrienes were secreted from eosinophils. We also analyzed the association between TEC and each polymorphism. Children who were heterozygous or homozygous for the minor allele of the PTGDR −441T/C or LTC4S −444A/C polymorphisms tended to have higher TEC than children who were homozygous for the common allele; however, the effect was not statistically significant (data not shown). Altogether, we thought that increment of eosinophil count in atopic asthmatics is result worth considering certainly. Increased levels of cysLTs have been detected in airways,19 exhaled breath condensates21 and induced sputum,22 and bronchial hyperresponsiveness has been induced by administration of cysLTs.35 PTGDR expression was increased by the region including −441C allele14 and increased expression of the PTGDR augmented the ability of PGD2 to recruit eosinophils and stimulate them to synthesize LTC4.18 According to our data, the combined effects of the LTC4S −444C and PTGDR −441C alleles may have an additive effect on increasing TEC. Ultimately, higher levels of LTC4 disrupt LTRA responsiveness in children with asthma (Figure 2).
A weakness of our study is that there is not a clear cutoff value that distinguishes responders from non-responders. However, to our knowledge, there are no published research findings that address this issue. The classification system used in this study enabled us to include 92 subjects, which was sufficient to analyze drug responsiveness. Second, other genes may be connected on LTRA responsiveness, for instance, cysLT1, which is receptor of leukotriene and interleukin-5, which is cytokine that acts as a growth and differentiation factor for eosinophils may be associated with LTRA responsiveness. However, we only investigated two polymorphisms in two genes. In the future, more studies are needed to validate these results with more genes in larger population. Third, EIB test is more accurate indoor than outdoor. We conducted free running at outdoor to provoke maximal stimulation of EIB and calculated temperature (19±58°C) and humidity (57±12%) during day of testing.30 We performed all of these study population using the same maneuver, although there might have been limited differences in the climatic conditions compared with the standard treadmill test. The last, two SNPs in this study were associated by genotype and combination at nominal level of significance. Despite these limitations, our data may use for drug responsiveness because we compared result of medication before and after in same subjects, also the current finding of association study on LTRA responsiveness helps to possible personalized medication.
In summary, we report for the first time that the PTGDR −441C allele seems to be associated with LTRA responsiveness and that increases in TEC are associated with the LTC4S −444C and PTGDR −441C allele. Individual polymorphisms may have a small influence in complex diseases such as asthma. However, a combination of polymorphisms in entire pathway gives help to understand complex disease. Our results suggest that there is variability in the response to LTRA that is related to genotype, and this information may help identify more selective therapeutic strategies.
References
Novak, N. & Bieber, T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 112, 252–262 (2003).
Shirakawa, I., Deichmann, K. A., Izuhara, I., Mao, I., Adra, C. N. & Hopkin, J. M. Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol. Today 21, 60–64 (2000).
Maggi, E., Del Prete, G. F., Parronchi, P., Tiri, A., Macchia, D., Biswas, P. et al. Role for T cells, IL-2 and IL-6 in the IL-4-dependent in vitro human IgE synthesis. Immunology 68, 300–306 (1989).
Yamaguchi, Y., Hayashi, Y., Sugama, Y., Miura, Y., Kasahara, T., Kitamura, S. et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J. Exp. Med. 167, 1737–1742 (1988).
Holgate, S. T. The inflammation-repair cycle in asthma: the pivotal role of the airway epithelium. Clin. Exp. Allergy 28, 97–103 (1998).
Lewis, R. A., Soter, N. A., Diamond, P. T., Austen, K. F., Oates, J. A. & Roberts, L. J. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129, 1627–1631 (1982).
Curzen, N., Rafferty, P. & Holgate, S. T. Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 42, 946–952 (1987).
Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K. et al. Prostaglandin D2 as a mediator of allergic asthma. Science 287, 2013–2017 (2000).
Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y. et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193, 255–261 (2001).
Boie, Y., Sawyer, N., Slipetz, D. M., Metters, K. M. & Abramovitz, M. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270, 18910–18916 (1995).
Oguma, T., Palmer, L. J., Birben, E., Sonna, L. A., Asano, K. & Lilly, C. M. Role of prostanoid DP receptor variants in susceptibility to asthma. N. Engl. J. Med. 351, 1752–1763 (2004).
Tsai, Y. J., Choudhry, S., Kho, J., Beckman, K., Tsai, H. J., Navarro, D. et al. The PTGDR gene is not associated with asthma in 3 ethnically diverse populations. J. Allergy Clin. Immunol. 118, 1242–1248 (2006).
Sanz, C., Isidoro-García, M., Dávila, I., Moreno, E., Laffond, E., Avila, C. et al. Promoter genetic variants of prostanoid DP receptor (PTGDR) gene in patients with asthma. Allergy 61, 543–548 (2006).
Li, J., Liu, Q., Wang, P., Li, H., Wei, C., Guo, C. et al. Lack of association between three promoter polymorphisms of PTGDR gene and asthma in a Chinese Han population. Int. J. Immunogenet. 34, 353–357 (2007).
Rouzer, C. A., Matsumoto, T. & Samuelsson, B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc. Natl Acad. Sci. USA 83, 857–861 (1986).
DeWitt, D. L. & Smith, W. L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl Acad. Sci. USA 85, 1412–1416 (1988).
O’Banion, M. K., Winn, V. D. & Young, D. A cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci. USA 89, 4888–4892 (1992).
Mesquita-Santos, F. P., Vieira-de-Abreu, A., Calheiros, A. S., Figueiredo, I. H., Castro-Faria-Neto,, H. C., Bandeira-Melo, C. et al. Cutting edge: prostaglandin D2 enhances leukotriene C4 synthesis by eosinophils during allergic inflammation: synergistic in vivo role of endogenous eotaxin. J. Immunol. 176, 1326–1330 (2006).
Freed, A. N., Wang, Y., McCulloch, S., Myers, T. & Suzuki, R. Mucosal injury and eicosanoid kinetics during hyperventilation-induced bronchoconstriction. J. Appl. Physiol. 87, 1724–1733 (1999).
Reiss, T. F., Hill, J. B., Harman, E., Zhang, J., Tanaka, W. K., Bronsky, E. et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52, 1030–1035 (1997).
Carraro, S., Corradi, M., Zanconato, S., Alinovi, R., Pasquale, M. F., Zacchello, F. et al. Exhaled breath condensate cysteinyl leukotrienes are increased in children with EIB. J. Allergy Clin. Immunol. 115, 764–770 (2005).
Hallstrand, T. S., Moody, M. W., Aitken, M. L. & Henderson##Jr, W. R. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 116, 586–593 (2005).
Kim, J. H., Lee, S. Y., Kim, H. B., Kim, B. S., Shim, J. Y., Hong, T. J. et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr. Pulmonol. 39, 162–166 (2005).
Kang, M. J., Lee, S. Y., Kim, H. B., Yu, J., Kim, B. J., Hong, S. J. et al. Association of IL-13 polymorphisms with LTRA drug responsiveness in Korean children with exercise-induced bronchoconstriction. Pharmacogenet. Genomics 18, 551–558 (2008).
Sampson, A. P., Siddiqui, S., Buchanan, D., Howarth, P. H., Holgate, S. T., Holloway, J. W. et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55, S28–S31 (2000).
Kedda, M. A., Shi, J., Duffy, D., Phelps, S., Yang, I., O’Hara, K. et al. Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. J. Allergy Clin. Immunol. 113, 889–895 (2004).
Torres-Galván, S. M., Cumplido, J. A., Buset, N., Caballero-Hidalgo, A., Blanco, C., Hernández, E. et al. 5-Lipoxygenase pathway gene polymorphisms: lack of association with asthma in a Spanish population. J. Investig. Allergol. Clin. Immunol. 19, 453–458 (2009).
Sampson, A. P., Pizzichini, E. & Bisgaard, H. Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J. Allergy Clin. Immunol. 111, 49–61 (2003).
O’Byrne, P. M. Leukotriene bronchoconstriction induced by allergen and exercise. Am. J. Respir. Crit. Care Med. 161, S68–S72 (2000).
Lee, S. Y., Kim, H. B., Kim, J. H., Kim, B. S., Kang, M. J. & Jang, S. O. et al Eosinophils play a major role in the severity of exercise-induced bronchoconstriction in children with asthma. Pediatr. Pulmonol. 41, 1161–1166 (2006).
Yoshikawa, T., Shoji, S., Fujii, T., Kanazawa, H., Kudoh, S., Hirata, K. et al. Severity of exercise induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma. Eur. Respir. J. 12, 879–884 (1998).
Koh, Y. I. & Choi, I. S. Blood eosinophil counts for the prediction of the severity of exercise-induced bronchospasm in asthma. Respir. Med. 96, 120–125 (2002).
Otani, K., Kanazawa, H., Fujiwara, H., Hirata, K., Fujimoto, S. & Yoshikawa, J. Determinants of the severity of exercise-induced bronchoconstriction in patients with asthma. J. Asthma 41, 271–278 (2004).
Duong, M., Subbarao, P., Adelroth, E., Obminski, G., Strinich, T., Inman, M. et al. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. Chest 133, 404–411 (2008).
Hay, D. W., Torphy, T. J. & Undem, B. J. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol. Sci. 16, 304–309 (1995).
Acknowledgements
We would like to thank all of the study participants. This study was supported by a grant of the Korea health 21 R&D Project, Ministry for Health, Welfare and Family Affairs, R.O.K. (A030001).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Kang, MJ., Kwon, JW., Kim, BJ. et al. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J Hum Genet 56, 284–289 (2011). https://doi.org/10.1038/jhg.2011.3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhg.2011.3
Keywords
This article is cited by
-
Asthma Pharmacogenomics: 2015 Update
Current Allergy and Asthma Reports (2015)
-
PTGDR polymorphisms and susceptibility to asthma: a meta-analysis
Molecular Biology Reports (2013)
-
The pharmacogenetics and pharmacogenomics of asthma therapy
The Pharmacogenomics Journal (2011)